F&FFinancial Insights

Financial Metrics

INDV Indivior Pharmaceuticals, Inc.
Range: 2016-01-01 to 2026-04-29
Chart Range:
% Change:

Financial Statements

Grouped by statement

Income Statement

Metrics: 6

Revenue

Q: 6 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2024-03-31 284000000.0 USD 10-Q 2025-05-01
Quarterly 2024-06-30 299000000.0 +5.3% USD 10-Q 2025-07-31
Quarterly 2024-09-30 307000000.0 +2.7% USD 10-Q 2025-10-30
Quarterly 2025-03-31 266000000.0 -13.4% USD 10-Q 2025-05-01
Quarterly 2025-06-30 302000000.0 +13.5% USD 10-Q 2025-07-31
Quarterly 2025-09-30 314000000.0 +4.0% USD 10-Q 2025-10-30
Annual 2022-12-31 901000000.0 USD 10-K 2025-03-03
Annual 2023-12-31 1093000000.0 +21.3% USD 10-K 2026-02-26
Annual 2024-12-31 1188000000.0 +8.7% USD 10-K 2026-02-26
Annual 2025-12-31 1239000000.0 +4.3% USD 10-K 2026-02-26

Gross Profit

Q: 6 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2024-03-31 246000000.0 USD 10-Q 2025-05-01
Quarterly 2024-06-30 220000000.0 -10.6% USD 10-Q 2025-07-31
Quarterly 2024-09-30 241000000.0 +9.5% USD 10-Q 2025-10-30
Quarterly 2025-03-31 221000000.0 -8.3% USD 10-Q 2025-05-01
Quarterly 2025-06-30 250000000.0 +13.1% USD 10-Q 2025-07-31
Quarterly 2025-09-30 230000000.0 -8.0% USD 10-Q 2025-10-30
Annual 2022-12-31 749000000.0 USD 10-K 2025-03-03
Annual 2023-12-31 919000000.0 +22.7% USD 10-K 2026-02-26
Annual 2024-12-31 957000000.0 +4.1% USD 10-K 2026-02-26
Annual 2025-12-31 994000000.0 +3.9% USD 10-K 2026-02-26

Operating Income

Q: 9 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2022-12-31 -77000000.0 USD 10-Q 2025-10-30
Quarterly 2023-12-31 -152000000.0 -97.4% USD 10-Q 2025-10-30
Quarterly 2024-03-31 75000000.0 +149.3% USD 10-Q 2025-10-30
Quarterly 2024-06-30 -118000000.0 -257.3% USD 10-Q 2025-10-30
Quarterly 2024-09-30 35000000.0 +129.7% USD 10-Q 2025-10-30
Quarterly 2024-12-31 46000000.0 +31.4% USD 10-Q 2025-10-30
Quarterly 2025-03-31 66000000.0 +43.5% USD 10-Q 2025-05-01
Quarterly 2025-06-30 72000000.0 +9.1% USD 10-Q 2025-07-31
Quarterly 2025-09-30 43000000.0 -40.3% USD 10-Q 2025-10-30
Annual 2022-12-31 -81000000.0 USD 10-K 2025-03-03
Annual 2023-12-31 -152000000.0 -87.7% USD 10-K 2026-02-26
Annual 2024-12-31 46000000.0 +130.3% USD 10-K 2026-02-26
Annual 2025-12-31 262000000.0 +469.6% USD 10-K 2026-02-26

Net Income

Q: 9 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2022-12-31 -42000000.0 USD 10-Q 2025-10-30
Quarterly 2023-12-31 -126000000.0 -200.0% USD 10-Q 2025-10-30
Quarterly 2024-03-31 61000000.0 +148.4% USD 10-Q 2025-10-30
Quarterly 2024-06-30 -97000000.0 -259.0% USD 10-Q 2025-10-30
Quarterly 2024-09-30 22000000.0 +122.7% USD 10-Q 2025-10-30
Quarterly 2024-12-31 21000000.0 -4.5% USD 10-Q 2025-10-30
Quarterly 2025-03-31 47000000.0 +123.8% USD 10-Q 2025-10-30
Quarterly 2025-06-30 18000000.0 -61.7% USD 10-Q 2025-10-30
Quarterly 2025-09-30 42000000.0 +133.3% USD 10-Q 2025-10-30
Annual 2022-12-31 -44000000.0 USD 10-K 2025-03-03
Annual 2023-12-31 -126000000.0 -186.4% USD 10-K 2026-02-26
Annual 2024-12-31 21000000.0 +116.7% USD 10-K 2026-02-26
Annual 2025-12-31 210000000.0 +900.0% USD 10-K 2026-02-26

EPS Basic

Q: 9 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2022-12-31 -0.3 USD/shares 10-Q 2025-10-30
Quarterly 2023-12-31 -0.92 -206.7% USD/shares 10-Q 2025-10-30
Quarterly 2024-03-31 0.45 +148.9% USD/shares 10-Q 2025-05-01
Quarterly 2024-06-30 -0.72 -260.0% USD/shares 10-Q 2025-07-31
Quarterly 2024-09-30 0.16 +122.2% USD/shares 10-Q 2025-10-30
Quarterly 2024-12-31 0.05 -68.8% USD/shares 10-Q 2025-10-30
Quarterly 2025-03-31 0.38 +660.0% USD/shares 10-Q 2025-05-01
Quarterly 2025-06-30 0.15 -60.5% USD/shares 10-Q 2025-07-31
Quarterly 2025-09-30 0.34 +126.7% USD/shares 10-Q 2025-10-30
Annual 2022-12-31 -0.32 USD/shares 10-K 2025-03-03
Annual 2023-12-31 -0.92 -187.5% USD/shares 10-K 2026-02-26
Annual 2024-12-31 0.05 +105.4% USD/shares 10-K 2026-02-26
Annual 2025-12-31 1.68 +3260.0% USD/shares 10-K 2026-02-26

EPS Diluted

Q: 9 | A: 4

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2022-12-31 -0.3 USD/shares 10-Q 2025-10-30
Quarterly 2023-12-31 -0.92 -206.7% USD/shares 10-Q 2025-10-30
Quarterly 2024-03-31 0.45 +148.9% USD/shares 10-Q 2025-05-01
Quarterly 2024-06-30 -0.72 -260.0% USD/shares 10-Q 2025-07-31
Quarterly 2024-09-30 0.16 +122.2% USD/shares 10-Q 2025-10-30
Quarterly 2024-12-31 0.05 -68.8% USD/shares 10-Q 2025-10-30
Quarterly 2025-03-31 0.38 +660.0% USD/shares 10-Q 2025-05-01
Quarterly 2025-06-30 0.14 -63.2% USD/shares 10-Q 2025-07-31
Quarterly 2025-09-30 0.33 +135.7% USD/shares 10-Q 2025-10-30
Annual 2022-12-31 -0.32 USD/shares 10-K 2025-03-03
Annual 2023-12-31 -0.92 -187.5% USD/shares 10-K 2026-02-26
Annual 2024-12-31 0.05 +105.4% USD/shares 10-K 2026-02-26
Annual 2025-12-31 1.64 +3180.0% USD/shares 10-K 2026-02-26

8-K Material Event Details

26 filings · 70 item records

This 8-K section tracks corporate event disclosures, not insider buy/sell sentiment. Insider trading direction is shown in the insider section below.

Event Type Distribution

Count per 8-K item

Insider Transaction History

17 transaction records

Net Insider Flow

Monthly open-market buy value minus open-market sell value

Monthly Insider Activity Mix

Share volume split between open-market trades, grants, and exercises

Transaction Value Timeline

Each circle = one priced transaction; size ∝ value

All Transactions

Date Insider Title Type Security Shares Price Total Value Post-Tx Shares
2026-03-14 Preblick Ryan Chief Financial Officer Exercise / conversion
M · derivative
Restricted Stock Units 6,302 $0 0
2026-03-14 Preblick Ryan Chief Financial Officer Other disposed transaction
F
Common Stock 2,843 $31.11 $88,446 320,751
2026-03-14 Preblick Ryan Chief Financial Officer Exercise / conversion
M
Common Stock 6,302 323,594
2026-03-13 Ryan Barbara Dir Open-market buy
P
Common Stock 8 $31.09 $249 5,724
2026-03-09 Ryan Barbara Dir Open-market buy
P
Common Stock 31 $32.56 $1,009 5,716
2026-03-06 Kingsley Stuart A Dir Open-market buy
P
Common Stock 940 $31.86 $29,953 5,582
2026-03-03 Anderson Woodrow D Chief Accounting Officer Exercise / conversion
M · derivative
Restricted Stock Units 5,946 $0 0
2026-03-03 Anderson Woodrow D Chief Accounting Officer Exercise / conversion
M · derivative
Performance Stock Units 23,975 $0 0
2026-03-03 Anderson Woodrow D Chief Accounting Officer Other disposed transaction
F
Common Stock 2,682 $31.98 $85,770 24,638
2026-03-03 Anderson Woodrow D Chief Accounting Officer Exercise / conversion
M
Common Stock 5,946 27,320
2026-03-03 Anderson Woodrow D Chief Accounting Officer Other disposed transaction
F
Common Stock 8,283 $31.98 $264,890 21,374
2026-03-03 Anderson Woodrow D Chief Accounting Officer Exercise / conversion
M
Common Stock 18,364 29,657
2026-02-10 Anderson Woodrow D Chief Accounting Officer Equity grant / award
A
Common Stock 6,903 $0.00 $0 11,293
2026-02-10 Barry Patrick A Chief Commercial Officer Equity grant / award
A
Common Stock 31,380 $0.00 $0 31,380
2026-02-09 Anderson Woodrow D Chief Accounting Officer Equity grant / award
A · derivative
Performance Stock Units 23,975 $0.00 $0 23,975
2026-01-26 Kingsley Stuart A Dir Equity grant / award
A
Common Stock 3,722 $0.00 $0 4,642
2026-01-05 Ryan Barbara Dir Open-market buy
P
Ordinary Shares 775 $35.39 $27,429 1,963

Regulatory Activity

Last 12 months to 2025-04-29
Insider Filings (Forms 3/4/5) — 12 months
10
Material Event Filings (8-K) — 12 months
23

8-K Material Event Filing Activity

Monthly count

Insider Trading Activity (Forms 3/4/5)

Monthly count
For informational purposes only — not guaranteed to be accurate or complete.